Marion E Meijer-Van Gelder

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
    Anne Sofie Schrohl
    University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK 1870 Frederiksberg C, Denmark
    BMC Cancer 9:322. 2009
  2. ncbi request reprint Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
  3. ncbi request reprint How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 11:7311-21. 2005
  4. ncbi request reprint HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
  5. doi request reprint MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
    F Germán Rodríguez-González
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 127:43-51. 2011
  6. ncbi request reprint Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer
    Els M J J Berns
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:1253-8. 2003
  7. doi request reprint Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
  8. doi request reprint Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
    Ton van Agthoven
    Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 27:542-9. 2009
  9. ncbi request reprint The prognostic value of BCAR1 in patients with primary breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam
    Clin Cancer Res 10:6194-202. 2004
  10. ncbi request reprint RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:827-36. 2003

Detail Information

Publications26

  1. pmc Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
    Anne Sofie Schrohl
    University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK 1870 Frederiksberg C, Denmark
    BMC Cancer 9:322. 2009
    ..We hypothesize that TIMP-1 high tumors are less sensitive to chemotherapy and accordingly that high tumor tissue levels are associated with shorter survival...
  2. ncbi request reprint Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
    ..Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system...
  3. ncbi request reprint How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 11:7311-21. 2005
    ..To evaluate the predictive value of the disintegrin and metalloproteinases, ADAM-9, ADAM-10, ADAM-11, and ADAM-12, and of the matrix metalloproteinases, MMP-2 and MMP-9, in patients with recurrent breast cancer treated with tamoxifen...
  4. ncbi request reprint HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
    ..However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both...
  5. doi request reprint MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
    F Germán Rodríguez-González
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 127:43-51. 2011
    ..Assessment of tumor levels and connected pathways could be helpful to improve treatment strategies...
  6. ncbi request reprint Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer
    Els M J J Berns
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:1253-8. 2003
    ..Mutant TP53 may up-regulate VEGF, whereas, on the other hand, wild-type TP53 may decrease VEGF production...
  7. doi request reprint Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
    ....
  8. doi request reprint Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
    Ton van Agthoven
    Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 27:542-9. 2009
    ..Here, we explored whether these BCAR genes provide predictive value for tamoxifen resistance and prognostic information for tumor aggressiveness in breast cancer patients...
  9. ncbi request reprint The prognostic value of BCAR1 in patients with primary breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam
    Clin Cancer Res 10:6194-202. 2004
    ..Here, we study the prognostic value of quantitative BCAR1 levels in a large series of breast cancer specimens...
  10. ncbi request reprint RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:827-36. 2003
    ..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease...
  11. ncbi request reprint Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 12:3319-28. 2006
    ..To evaluate the prognostic value of cyclin E with a quantitative method for lymph node-negative primary breast cancer patients...
  12. doi request reprint Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  13. ncbi request reprint Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Chem 53:1280-8. 2007
    ..TIMP-1 protein is a prognostic factor for recurrence-free and overall survival (OS) time in breast cancer. We evaluated the prognostic value of TIMP1 mRNA and a novel TIMP1 mRNA splice variant in 1301 primary breast cancer patients...
  14. ncbi request reprint Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  15. doi request reprint The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
    Ron H N van Schaik
    Erasmus MC Rotterdam, The Netherlands
    Pharmacogenomics 12:1137-46. 2011
    ..Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients...
  16. ncbi request reprint Molecular profiling of platinum resistant ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 118:1963-71. 2006
    ..A larger independent multicentre study should further confirm whether this 9-gene set can identify the patients who will not respond to platinum-based chemotherapy and could benefit from other therapies...
  17. ncbi request reprint Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
    John W M Martens
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 65:4101-17. 2005
    ..Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer...
  18. ncbi request reprint Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
    ..To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling...
  19. doi request reprint CHEK2 1100delC and male breast cancer in the Netherlands
    Marijke Wasielewski
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:397-400. 2009
    ..1% Dutch population frequency assessed in 1,692 individuals (P = 0.05, OR = 4.1, 95% CI 1.2-14.3). Our data suggest that, in the Netherlands, CHEK2 1100delC is associated with an increased risk for MBC...
  20. ncbi request reprint DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
    Inko Nimmrich
    Department of Biomedical Research and Development and Technology Development, Epigenomics AG, Berlin, Germany
    Breast Cancer Res Treat 111:429-37. 2008
    ..In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression...
  21. ncbi request reprint Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  22. ncbi request reprint Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor
    Matthias Kotzsch
    Institute of Pathology, Dresden University of Technology, Fetscherstr 74, 01307, Dresden, Germany
    Breast Cancer Res Treat 111:229-40. 2008
    ..To evaluate the pure prognostic impact of the uPA-receptor splice variant uPAR-del4/5 for lymph node-negative breast cancer patients, and to identify differentially expressed genes associated with high or low uPAR-del4/5 mRNA levels...
  23. ncbi request reprint Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer
    Anne Sofie Schrohl
    The Royal Veterinary and Agricultural University, Department of Pharmacology and Pathobiology, Frederiksberg C, Denmark
    Clin Cancer Res 10:2289-98. 2004
    ....
  24. ncbi request reprint Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
    Cancer Res 62:4617-22. 2002
    ....
  25. ncbi request reprint Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer
    Anne Sofie Schrohl
    Department of Veterinary Pathobiology, The Royal Veterinary and Agricultural University, Frederiksberg C, Denmark
    Clin Cancer Res 12:7054-8. 2006
    ....
  26. ncbi request reprint Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer
    Selina Raguz
    Medical Research Council Clinical Sciences Centre, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, London, United Kingdom
    Int J Cancer 122:1058-67. 2008
    ....